Skip to main content

Advertisement

Table 3 Safety of thromboprophylaxis with LMWH compared with UFH in medical patients.

From: An update on prevention of venous thromboembolism in hospitalized acutely ill medical patients

Study Patients LMWH UFH Safety
Harenberg et al.1990 [30] 166 Dalteparin 1500 aPTT units s.c. o.d. 5000 IU s.c. t.i.d. Similar incidence of adverse events in both groups. Haematomas were significantly smaller in diameter in the LMWH group
Bergmann and Neuhart, 1996 [31] 439 Enoxaparin 20 mg s.c. o.d. 5000 IU s.c. b.i.d. Similar incidence of adverse events in both groups
Lechler et al. 1996 [32] 959 Enoxaparin 40 mg s.c. o.d. 5000 IU s.c. t.i.d. Fewer major bleeding complications and significantly fewer injection-site haematomas (>5 cm diameter) in the enoxaparin group
Harenberg et al. 1996 [33] 1,968 Nadroparin 36 mg s.c. o.d. 5000 IU s.c. t.i.d. Major bleeding was rare. Local haematomas (>2.5 cm diameter), local erythema and local allergic reactions were more frequent in the UFH group.
Kleber et al. 2003 [34] 665 Enoxaparin 40 mg s.c. o.d. 5000 IU s.c. t.i.d. Significantly fewer adverse events in the enoxaparin group
  1. aPTT, activated partial thromboplastin time; b.i.d., twice daily; LMWH, low-molecular-weight heparin; o.d., once daily; s.c., subcutaneously; t.i.d., three times daily; UFH, unfractionated heparin.